AUS
NZ
UK
CA
USA
IND
Highlights
- New capabilities distinguish between CALR type 1 and type 2 mutations.
- Alignment with the latest NCCN guidelines enhances clinical decision-making.
- First quantitative PCR-based panel offering detailed CALR subtyping in MPN diagnostics.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has announced a significant advancement in the diagnosis and management of myeloproliferative neoplasms (MPNs) with the launch of an enhanced version of its Bloodhound MPN panel. This updated assay now allows clinicians to differentiate between CALR type 1 and type 2 mutations, an important development in the realm of cancer diagnostics that promises to improve patient care and therapeutic outcomes.
The significance of CALR mutations in MPNs cannot be overstated. These mutations are common in patients with MPNs and have critical implications for prognosis and treatment strategies. Understanding whether a patient carries CALR type 1 or type 2 mutations can guide healthcare providers in making informed decisions about the most effective treatment plans. This differentiation aligns with the latest updates from the National Comprehensive Cancer Network (NCCN), specifically Version 2.2024, released on August 8, 2024, which emphasizes the necessity of precise mutation identification in managing MPNs.
Precipio’s Bloodhound MPN panel stands out as the only quantitative PCR-based test on the market that offers this level of detail regarding CALR subtyping. The ability to identify these mutations, alongside other relevant genetic markers, enhances the molecular evaluation of MPNs. “As science and discovery constantly evolve the diagnostic world, Precipio is committed to maintaining its competitive advantage and being at the forefront of our industry,” stated Ilan Danieli, CEO of Precipio. “Our customers and their patients will continue to benefit from access to cutting-edge technologies combined with the highest clinical value, enhancing patient care.”
The clinical implications of CALR subtyping are profound. Research has shown that the type of CALR mutation can affect the prognosis of the disease, indicating the severity and likely progression of MPNs. For instance, patients with different CALR mutations may exhibit varying responses to treatment, particularly in cases where dual mutations (such as JAK2 and CALR) are present. In such scenarios, accurately identifying the subtype of the CALR mutation can influence the choice of targeted therapies, leading to more tailored and effective treatment approaches.
With healthcare providers increasingly seeking comprehensive data to inform their clinical decisions, Precipio’s Bloodhound MPN assay arrives at a crucial moment. The detailed insights provided by this new capability will enable physicians to better classify MPN subtypes and identify which CALR-positive patients are likely to benefit from specific CALR-targeted therapies. This is a significant step forward in the management of MPNs, potentially improving outcomes for countless patients.
